Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
← catalyst calendarNCT07214779 · readout in 819 d
Sponsored by Incyte Corporation (industry) · INCY — their whole pipeline →. With ENGOT Foundation, GOG Foundation.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
466estimated
Sites
181
Countries
Australia, Belgium, Canada +13
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-09 | actual | When the study began enrolling |
| Primary completion | 2028-11-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-05-14 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Ovarian Cancer
Interventions
- Drug: INCB123667
- Drug: Investigator's choice of chemotherapy — also filed as paclitaxel, pegylated liposomal doxorubicin (PLD), gemcitabine, topotecan
Primary outcomes
what the primary-completion date above is the date OFProgression-Free Survival (PFS) by BICR
measured Up to 2 years
Overall Survival (OS)
measured Up to 2 years
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed